Evaluation of Immune Responses to a Trimerically Stabilized gp120 Immunogen

三聚稳定 gp120 免疫原的免疫反应评估

• 批准号: 10012926
• 负责人: RANAJIT PAL
• 金额: $ 23.49万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-15 至 2020-07-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10012926
• 关键词: AIDS Vaccines; Advanced Development; Antigens; Award; Clinical; Complement; Contracts; Development; Evaluation; Evaluation Studies; Funding; Grant; HIV Envelope Protein gp120; HIV vaccine; HIV-1; Immune response; Immunotherapy; Investigator-Initiated Research; Local Microbicides; Macaca mulatta; Modality; National Institute of Allergy and Infectious Disease; Prevention; Prevention strategy; Research Design; Research Personnel; Research Project Grants; Resources; Vaccine Research; Vaccines; neutralizing antibody; nonhuman primate; pre-clinical; preclinical evaluation; preclinical study; programs; vaccine candidate; vaccine development; vaccine evaluation

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers.The primary activity is to studies to evaluate Immune responses to a trimerically stabilized gp120 immunogen.

HIV疫苗和其他预防策略的开发依赖于在临床前研究中使用非人灵长类动物来推进有效的艾滋病候选疫苗的开发，并促进有效的局部杀微生物剂和其他预防方式或基于免疫的疗法的开发。 NIAID 猿猴疫苗评估单位 (SVEU) 合同应提供主要支持艾滋病疫苗临床前评估的非人类灵长类动物资源。 SVEU 开展研究以支持广泛的研究人员正在开发的疫苗。这些研究补充了 NIAID 支持的基础疫苗研究和疫苗评估研究，这些研究通过 R01（研究者发起的研究）拨款、HIVRAD（艾滋病毒疫苗研究和设计计划）拨款、IPCAVD（临床前-临床综合艾滋病疫苗开发）拨款和 NHP 联盟资助奖项。 SVEU 还对公司或其他研究人员提供的候选疫苗进行研究。主要活动是研究评估对三聚体稳定的 gp120 免疫原的免疫反应。